Journal
MOLECULAR BIOLOGY OF THE CELL
Volume 26, Issue 22, Pages 3946-3953Publisher
AMER SOC CELL BIOLOGY
DOI: 10.1091/mbc.E15-07-0456
Keywords
-
Categories
Funding
- National Institutes of Health [NIA R00AG033176, R01AG040081]
- U.S. Department of Energy [DE-AC02-05CH11231]
- Congressionally Directed Medical Research Programs/Breast Cancer Research Program Era of Hope Scholar Award
- California Breast Cancer Research Program
- Anita Tarr Turk Fund for Breast Cancer Research [20IB-0109]
Ask authors/readers for more resources
Stiffness is a biophysical property of the extracellular matrix that modulates cellular functions, including proliferation, invasion, and differentiation, and it also may affect therapeutic responses. Therapeutic durability in cancer treatments remains a problem for both chemotherapies and pathway-targeted drugs, but the reasons for this are not well understood. Tumor progression is accompanied by changes in the biophysical properties of the tissue, and we asked whether matrix rigidity modulated the sensitive versus resistant states in HER2-amplified breast cancer cell responses to the HER2-targeted kinase inhibitor lapatinib. The antiproliferative effect of lapatinib was inversely proportional to the elastic modulus of the adhesive substrata. Down-regulation of the mechanosensitive transcription coactivators YAP and TAZ, either by siRNA or with the small-molecule YAP/TEAD inhibitor verteporfin, eliminated modulus-dependent lapatinib resistance. Reduction of YAP in vivo in mice also slowed the growth of implanted HER2-amplified tumors, showing a trend of increasing sensitivity to lapatinib as YAP decreased. Thus we address the role of stiffness in resistance to and efficacy of a HER2 pathway-targeted therapeutic via the mechanotransduction arm of the Hippo pathway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available